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Induction of Phenotype Switching
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Melanoma cells can switch from a highly proliferative, less invasive state to a
highly invasive, less proliferative state, a phenomenon termed phenotype
switching. This results in a highly heterogenous tumor, where a slow-growing,
aggressive population of cells may resist tumor therapy, and it predicts tumor
recurrence. Here we discuss the observation made by Widmer et al. that hypoxia
may drive phenotype switching.
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Melanoma is the deadliest form of skin
cancer and, although only responsible
for 5% of all skin cancer cases,
it accounts for over 70% of skin
cancer–related deaths. Melanomas dis-
play extensive heterogeneity and
demonstrate a high degree of pheno-
typic plasticity. It has been observed
that a subpopulation of melanoma cells
appears to downregulate signaling path-
ways associated with proliferation when
they migrate (Hoek et al., 2008; Ghislin
et al., 2012). This switch from a
proliferative phenotype to a migratory
or invasive phenotype is achieved
by decreases in the expression of
genes associated with melanocyte
differentiation and pigment production,
such as MART1 and GP100, and by
increases in genes such as WNT5A
(Dissanayake et al., 2008) and FGF2
(Reiland et al., 2006). Melanocyte
differentiation antigens such as MART1
and GP100 are regulated by MITF, a
critical mediator in the transformation
of melanocytes and the growth and
proliferation of primary melanomas
(Haq and Fisher, 2011). In line with
this concept of phenotype switching is
the fact that the expression of MITF
and its downstream effectors are often
decreased in metastatic melanoma
(Dissanayake et al., 2008). We do not
yet understand completely the factors
that promote phenotype switching
in melanoma, nor the implications of
changes in the microenvironment for
the development of this phenotypic
plasticity.
In the current issue of JID, Widmer
et al. (2013) demonstrate that
one microenvironmental factor that
can influence phenotype switching is
hypoxia. They demonstrate that in
tissue biopsies, melanoma cells that
have decreased expression of melano-
cyte differentiation antigens correlate
with hypoxic regions within the tumor,
as determined by their expression of
GLUT1 and HIF1a. On the basis of
the phenotype switching theory, this
could imply that the cells within the
hypoxic regions are more metastatic.
However, the mechanisms are clearly
more complex, as hypoxia may be
inducing changes leading to cell death
in some cells while promoting invasion
in others. Either of these opposing
outcomes would result in decreased
expression of melanocyte differen-
tiation antigens. This complexity is
further evidenced by the fact that, in
this study, the expression of some genes
involved in invasion, and known to
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in vitro and in vivo (e.g., Wnt5A),
were downregulated in hypoxic cells.
Similarly, the expression of some genes
involved in proliferation, and previously
shown to be downregulated in metastatic
melanoma, were elevated. However,
of the genes examined, those involved
in proliferation were more likely to be
downregulated during hypoxia, whereas
genes involved in invasion were more
likely to be upregulated, suggesting that
the hypoxic microenvironment promotes
invasion. The authors confirmed this
using in vitro invasion assays, and
other studies have confirmed in vivo
that hypoxia can increase melanoma
metastasis.
A key finding in the Widmer study is
that a hypoxic microenvironment can
downregulate the expression of MITF.
This is in keeping with a study by
Cheli et al. (2012), which also demon-
strated that a hypoxic microenvironment
decreases MITF expression and
increases tumorigenic properties of
melanoma cells. In that study, the
authors showed that the downregula-
tion of MITF was mediated through the
hypoxia-inducible factor 1a (HIF1a) and
the transcription factor Bhlhb2 (basic
helix–loop–helix domain containing,
class B2). Further, the Cheli study
showed that knocking out MITF is suffi-
cient to increase metastatic potential
of both mouse and human cells
(Cheli et al., 2012). This correlated
with an increase in fibronectin and
snail, two markers of a more
mesenchymal, invasive phenotype.
Together, these studies indicate that
the hypoxia-induced downregulation of
MITF can induce a phenotype switch to
a more metastatic phenotype. The
Widmer study has also demonstrated
that once hypoxia-induced phenotype
switching has occurred, returning the
cells to normoxic conditions does not
reverse the increased invasive potential.
This may be due to the upregulation
of certain mesenchymal markers such
as vimentin, which, once expressed, are
difficult to repress.
In addition to demonstrating that
hypoxia guides a switch to a more
invasive phenotype, via the downregu-
lation of MITF, these data may have
significant implications for melanoma
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therapy. A recent advancement in ther-
apy for melanoma is the clinical
approval of inhibitors of mutant BRAF
(BRAFV600E). Mutations in the BRAF
oncogene, which signals downstream
of NRAS to activate mitogen-activated
protein kinase (MAPK) signaling, can
be found in over 60% of patients.
Although initial responses to the avail-
able BRAF inhibitors are usually good,
resistance develops quite quickly.
Understanding the mechanisms that
guide this resistance is a major area
of interest in the melanoma field. To
date, very few studies have addressed
the role of microenvironmental changes
such as hypoxia in the development
of resistance to BRAF inhibitors. How-
ever, an older study demonstrated
that mutant BRAF increased HIF1a in
melanoma cells via increased MAPK
signaling, and that knockdown of BRAF
(mutant and wild type) decreased cell
survival significantly under hypoxic
conditions (Kumar et al., 2007). A very
recent study has now shown that BRAF
activation suppresses MITF, which in
turn affects oxidative phosphorylation
in melanoma (Haq et al., 2013). Low
levels of MITF corresponded to resis-
tance to BRAF inhibitors. Because
tumors that are resistant to BRAF
inhibitors have elevated MAPK signal-
ing, it would follow that they have ele-
vated levels of HIF1a and, subsequently,
less MITF. Indeed, a previous study
from the Dummer laboratory demon-
strated that invasive phenotype cells
(low MITF) are less susceptible to
MAPK inhibition and that exposure
of proliferative phenotype cells to
BRAF inhibitors results in the expres-
sion of invasive phenotype markers
(Zipser et al., 2011).
These data, taken together, highlight
how mechanisms that guide metastasis
might also promote therapy resistance,
resulting in a highly aggressive tumor
(Figure 1). Clearly, the transcription
factor MITF also has a critical role in
both these processes. Understanding
how hypoxia can guide not only metas-
tasis but also therapy resistance to BRAF
inhibitors could be of great value in
designing novel therapies for the treat-
ment of melanoma. Targets of MITF may
prove, in turn, to be viable targets for
enhancing the efficacy of current inhi-
bitors or even as targets of stand-alone
therapies.
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Clinical Implications
 Hypoxia guides a switch of melanoma cells to a more invasive phenotype,
via the downregulation of MITF.
 Thus, the environment in which melanoma cells find themselves may
affect their invasive potential.
Microenvironmental changes such as hypoxia may also facilitate the
development of resistance to BRAF inhibitors.
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Figure 1. Schematic overview of phenotype switching in melanoma, and the effects of hypoxia thereon.
Following transformation of melanocytes, melanoma progresses through the traditional radial and vertical
growth phases, where tumor cells eventually come into contact with the blood (red line) or lymphatic
system (green). At the point of transformation (green box), a less metastatic and more proliferative
phenotype is observed (left blue box). As progression occurs, so does phenotype switching, until a less
proliferative highly metastatic gene profile can be seen (right blue box) as tumor cells enter the vertical
growth/metastatic phase. This progression can be enhanced further by changes in the tumor
microenvironment, such as an increased hypoxic state.
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